Marta Farres-Ferran

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Successful Treatment of Severe Refractory Chronic Actinic Dermatitis with Upadacitinib: A Case Series of Four Patients.

Successful Treatment of Severe Refractory Chronic Actinic Dermatitis with Upadacitinib: A Case Series of Four Patients.

Journal: Clinical and experimental dermatology

Published: February 20, 2026

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Journal: Actas dermo-sifiliograficas

Published: December 31, 2025

Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.

Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.

Journal: PloS one

Published: March 05, 2025

Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice.

Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical Practice.

Journal: Actas dermo-sifiliograficas

Published: September 12, 2024

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Journal: Actas dermo-sifiliograficas

Published: May 15, 2024

Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.

Journal: Actas dermo-sifiliograficas

Published: January 25, 2024

[Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients.

[Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients.

Journal: Actas dermo-sifiliograficas

Published: November 20, 2023

[Translated article] Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study.

[Translated article] Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study.

Journal: Actas dermo-sifiliograficas

Published: October 09, 2023

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Journal: Journal of the American Academy of Dermatology

Published: August 04, 2020

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry.

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry.

Journal: Actas dermo-sifiliograficas

Published: February 25, 2020

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

Journal: Journal of the American Academy of Dermatology

Published: October 08, 2019

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.

Journal: Actas dermo-sifiliograficas

Published: July 10, 2017

Showing 1-12 of 12

Last Updated: 09/26/2026